Over 30% of metastatic HR+ breast cancer patients develop endocrine resistance, leading to disease progression; the underlying mechanisms are complex and involve ER alterations, cross-talk with growth pathways (PI3K/AKT/mTOR, CDK4/6), and changes in the tumor microenvironment. Here, MTOR is linked to breast cancer.